STAT

Trump often goes off script. What does that mean for his drug pricing speech?

STAT asked nearly a dozen lobbyists and other experts about what they're predicting for the president's drug pricing speech this week.
Source: Evan Vucci/AP

WASHINGTON — President Trump is expected to deliver a major address on drug prices this week. And perhaps more than with any other president, Washington is wondering: What will he say?

There’s the version of the speech that top health officials have been touting and previewing for the last several weeks — the serious, “comprehensive strategy” that will result in a “profound modernization” of how the federal government pays for at least some drugs, to hear health secretary Alex Azar or FDA Commissioner Scott Gottlieb tell it.

But neither of those men will be behind the teleprompter this week. Because this is Trump, there is another possible version of the speech on everyone’s minds: the version in which he rips up his speech or otherwise ventures off script.

“This is not him waking up, watching ‘Fox & Friends’ and losing his s—. It’s a planned speech that HHS is behind,” one hospital and insurer lobbyist said. “Investors will be watching more closely, and going off script is a much bigger deal.”

There’s a small but real chance that what he says could galvanize the public behind a given idea — or come close

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

Related Books & Audiobooks